Community curated by people like you

BioNTech stories

Nov 6, 2026

GSK and Moderna settle patent dispute over COVID and RSV vaccines

GSK has settled lawsuits accusing Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, resolving a major intellectual property dispute between the two drugmakers.

Nov 6, 2026·2 sources

00

Top claims

▪GSK and Moderna settled all pending patent infringement lawsuits regarding Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV vaccine mResvia
▪Moderna reported third-quarter 2026 total revenue of $1.313 billion, representing a 29% increase from $1.016 billion in the third quarter of 2025
▪The U.S. Food and Drug Administration granted accelerated approval for Moderna's mFLUSIVA for adults aged 65 and older, contingent on a confirmatory efficacy study

Topics

COVID-19 vaccines Pharmaceutical earnings Intellectual property & trade MRNA vaccine technology Pharmaceutical Industry Pharmaceutical patents

Related entities

Delaware Pfizer United States